Skip to content
Get Claritide

Libido

PT-141 + a PDE5 inhibitor

An actual clinical programme rather than a community invention: Palatin ran a Phase 2 of bremelanotide co-administered with a PDE5 inhibitor in men who did not respond to a PDE5 inhibitor alone. We could not find a topline result.

At a glance

What is in it
Sold as
Separate vials
The evidence
Palatin announced an open-label dose-escalation Phase 2 of roughly 50 participants, with topline anticipated at the end of 2024. No result has been published that we could locate, so the outcome is unknown rather than negative. PT-141 itself is approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder, not for men, not for postmenopausal women, and not to enhance performance.Combination-specific research is limited. Treat each compound’s evidence as separate unless a study of the combination itself is named here, and review the complete plan with a qualified clinician.

Not runnableBoth agents are vasoactive and they push blood pressure in opposite directions. This is an ongoing clinical programme with no published topline result, not a home protocol.

Open the calculator

Running this stack, with the schedule, the vials it takes and a log of what you took, happens in the app: Claritide for iPhone.

Context

Why people explore it

Common reasons for exploring it

  • Anyone who has seen this pairing offered by a telehealth provider and wants to know what is actually known about it

Where clinician input matters

  • Anyone with uncontrolled hypertension or known cardiovascular disease
  • Anyone treating this as a home protocol. It is an unfinished clinical programme.
Mechanism

The science

Each compound's mechanism, in plain English. The rationale for combining them is pharmacologic, not proven.
Read the compound mechanisms
PT-141The Desire Drug

Bremelanotide is a non-selective melanocortin receptor agonist. The label states the potency order explicitly: MC1R, then MC4R, then MC3R, then MC5R, then MC2R. MC4R is the receptor usually invoked to explain effects on sexual desire, and the label is equally explicit that the exact mechanism by which bremelanotide improves desire is unknown, so MC4R involvement is a hypothesis, not a switch anyone has found. MC1R is the receptor on melanocytes that drives pigment production, and it is the one bremelanotide binds most strongly. That is not a footnote; it is the mechanistic origin of the pigmentation side effect.

The protocol

Commonly researched ranges

Commonly researched ranges reported in our material. Not a recommendation, and not a prescription.
  • PT-1411.75 mg

    Maximum one dose per 24 hours; more than 8 doses per month is not recommended · Subcutaneous, at least 45 minutes before anticipated sexual activity

    Prescription
  • PT-141: The label dose. The PDE5 inhibitor half of this combination is a prescription medication outside this library, and we do not publish a dose for it.
Duration
Episodic, not cyclical. There is no ongoing schedule.
Reconstitution

Mixing each compound

Concentration (mg/mL) = vial mg ÷ BAC water mL. Never mix two peptides in the same syringe: we found no study showing it is safe, and mixed drugs can lose activity even when they look unchanged.
PT-141

Not established in available literature. Use the figures printed on your own vial.

Expectations

Week by week

What our material describes people reporting for each compound. Nobody has published a timeline for the combination itself.

PT-141

  1. Within 1 hour of a dose

    Peak plasma concentration. Nausea, if it happens, typically starts inside this window. It affected 40% of patients in trials and 13% needed an anti-emetic.

  2. 2–4 hours after a dose

    Peak of the transient blood-pressure effect: systolic up about 6 mmHg, diastolic up about 3 mmHg, heart rate down about 5 bpm. This is why uncontrolled hypertension and known cardiovascular disease are absolute contraindications.

Budget

What it costs

Not established in available literature for any compound in this stack. Claritide’s cost engine will track what you actually pay once you log a vial.

Before you start

Cautions

  • The two agents oppose each other on blood pressure. PT-141 raises it transiently while PDE5 inhibitors lower it: systolic +6 mmHg, diastolic +3 mmHg, peaking 2–4 hours after the dose. That is the reason this is not presented as something to do at home.
  • Uncontrolled hypertension and known cardiovascular disease are absolute contraindications on the PT-141 label.
  • The monthly ceiling is a real number with a real reason behind it. Focal hyperpigmentation occurred in about 1% of patients at up to 8 doses a month, and in 38% when the drug was given daily for 8 days. The affected areas included face, gingiva and breasts, with higher risk in darker skin, and resolution was not confirmed in all patients.
  • PT-141 may significantly decrease systemic exposure of orally administered naltrexone, and may slow gastric emptying enough to reduce absorption of other oral medications.
  • Compounded intranasal PT-141 is widely sold. FDA placed a clinical hold on the intranasal bremelanotide programme in 2007 after dose-dependent blood pressure elevations in male erectile dysfunction trials; the route had wide variability in bioavailability. Palatin abandoned it and reformulated for subcutaneous use.
  • Nausea affected 40% of patients on the label, 13% of whom needed an anti-emetic, with onset within an hour.

Absence from this list does NOT mean safety. It means lack of research.

Every stack here is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.